Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CTLA-4
Biotech
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Bristol Myers Squibb is walking away from CytomX's potential successor to Yervoy and wiping $300 million off the value of the alliance in the process.
Nick Paul Taylor
Mar 12, 2024 7:07am
Agenus lays off 25%, sidelines programs to focus on cancer combo
Aug 23, 2023 11:04am
BioNTech's $200M bet on next-gen Yervoy triggers tumor responses
Jun 2, 2023 10:00am
ESMO: AstraZeneca's bispecific shows promise but limited by dose
Sep 11, 2022 4:20am
Cancer-killing virus boosts I-O responses in mice
Jan 15, 2020 2:00pm
Immuno-oncology combo for glioblastoma extends survival in mice
Dec 23, 2019 11:00am